The emergence of multidrug-resistant (MDR) Mycobacterium tuberculosis (Mtb) strains, i.e. strains resistant at least to isoniazid (INH) and rifampin (RMP), the two most powerful first-line drugs for the treatment of tuberculosis (TB), represents a worldwide health care problem. Patients with MDR strains should receive therapy based on individual drug susceptibility testing (DST), including residual first-line (streptomycin, SM; ethambutol, EMB; and pyrazinamide, PZA) and second-line (ofloxacin, kanamycin, capreomycin, ethionamide, p-aminosalicylic acid, cycloserine) anti-tuberculosis (TB) drugs. MDR TB has been reported as a major problem in former Soviet Union countries . Many TB programs have been described, based on DST for INH, RMP, SM, and EMB and, in some cases, for second- line drugs, but not for PZA. PZA is currently considered the third most important drug in the treatment of TB but it is not routinely tested for DST in most countries due to the requirement for an acid pH of the medium to demonstrate drug activity. PZA testing, when available, has mainly been done with the Wayne method; in later studies, BACTEC testing became more common.

Pyrazinamide Resistance In Multidrug-Resistant Strains of Mycobacterium tuberculosis Isolated in Abkhazia

ORRU, GERMANO;
2007-01-01

Abstract

The emergence of multidrug-resistant (MDR) Mycobacterium tuberculosis (Mtb) strains, i.e. strains resistant at least to isoniazid (INH) and rifampin (RMP), the two most powerful first-line drugs for the treatment of tuberculosis (TB), represents a worldwide health care problem. Patients with MDR strains should receive therapy based on individual drug susceptibility testing (DST), including residual first-line (streptomycin, SM; ethambutol, EMB; and pyrazinamide, PZA) and second-line (ofloxacin, kanamycin, capreomycin, ethionamide, p-aminosalicylic acid, cycloserine) anti-tuberculosis (TB) drugs. MDR TB has been reported as a major problem in former Soviet Union countries . Many TB programs have been described, based on DST for INH, RMP, SM, and EMB and, in some cases, for second- line drugs, but not for PZA. PZA is currently considered the third most important drug in the treatment of TB but it is not routinely tested for DST in most countries due to the requirement for an acid pH of the medium to demonstrate drug activity. PZA testing, when available, has mainly been done with the Wayne method; in later studies, BACTEC testing became more common.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11584/16324
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact